Published Peer-reviewed Initial Data from BioCardia Pivotal Phase 3 Clinical Trial of CardiAMP Demonstrates Improvement in Heart Failure Patients Measured by Exercise Outcomes and Cardiac Function
October 26, 2020 07:30 ET
|
BioCardia, Inc.
Paper Published in International Journal of Cardiology Demonstrates Safety and Tolerability While Showing Functional Improvement at Six Months SAN CARLOS, Calif., Oct. 26, 2020 (GLOBE...
Teneobio Announces a Research Collaboration and License Agreement With ArsenalBio
October 21, 2020 08:00 ET
|
TeneoBio, Inc
NEWARK, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical-stage biotechnology company developing engineered bispecific antibodies to treat cancer, today announced that it has...
Data to Be Presented at IDWeek™ 2020 Demonstrate the Economic and Clinical Burden of Respiratory and Multi-Virus Infections in Allogeneic Hematopoietic Cell Transplantation Recipients
October 21, 2020 07:30 ET
|
AlloVir Inc.
CAMBRIDGE, Mass., Oct. 21, 2020 (GLOBE NEWSWIRE) -- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced that health outcomes analyses to be presented at IDWeek™ 2020...
Competitive Landscape Analysis of Recent Cell and Gene Therapy Innovations, H2 2020 Report
October 21, 2020 05:58 ET
|
Research and Markets
Dublin, Oct. 21, 2020 (GLOBE NEWSWIRE) -- The "Competitive Landscape Analysis of Recent Cell and Gene Therapy Innovations" report has been added to ResearchAndMarkets.com's offering. This...
Global Cell Therapy Yescarta Kymriah Market Growth Size Sales Clinical Trials Pipeline Report 2027
October 21, 2020 02:40 ET
|
KuicK Research
DELHI, India, Oct. 21, 2020 (GLOBE NEWSWIRE) -- "Global Cell Therapy Market, Therapy Price, Dosage & Clinical Trials Insight 2027" Report Highlights: Global Cell Therapy Market Opportunity:...
Bone Therapeutics: Le produit de thérapie cellulaire allogénique, ALLOB, montre un taux de fusion des vertèbres lombaires de 90% à 24 mois dans l’étude de phase IIa
October 14, 2020 01:00 ET
|
Bone Therapeutics SA
90% des patients présentent une fusion osseuse ainsi que de fortes améliorations cliniques de la capacité fonctionnelle et de la réduction de la douleur, à 24 mois de suivi, avec un bon profil de...
Bone Therapeutics’ allogeneic cell therapy product, ALLOB, shows 90% fusion rate at 24 months in Phase IIa study in lumbar spinal fusion
October 14, 2020 01:00 ET
|
Bone Therapeutics SA
90% of patients show bone fusion as well as strong clinical improvements in function and pain at 24 months follow-up period with a good product safety profile Gosselies, Belgium, 14 October...
Vineti Extends Series C Funding Round to $68M with an Expanded Investor Coalition
October 13, 2020 09:00 ET
|
Vineti
This $33 million extension to Vineti’s Series C in February 2020 will be used to further grow the company’s leading enterprise platform for advanced therapies and support its mission of...
Bone Therapeutics participe à la conférence virtuelle Cell & Gene Meeting on the Mesa
October 12, 2020 01:00 ET
|
Bone Therapeutics SA
Gosselies, Belgique, le 12 octobre 2020, 7h00 CEST – BONE THERAPEUTICS (Euronext Bruxelles et Paris : BOTHE), société de biotechnologie spécialisée dans le développement de thérapies cellulaires...
Bone Therapeutics to present at 2020 Virtual Cell & Gene Meeting on the Mesa
October 12, 2020 01:00 ET
|
Bone Therapeutics SA
Gosselies, Belgium, 12 October 2020, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases,...